Table 1. Distribution of patient demographics, susceptibility testing results and major spoligotypes according to phase of testing (2006-2007 vs. 2008-2012).
| Characteristic | Earlier phase 2006-2007 (n = 1,128) | Later phase 2008-2012 (n = 484) | p-value |
|---|---|---|---|
| Median age, years (IQR) | 49 (32-63) | 47 (30-63) | 0.267 |
| Age distribution: | 0.442 | ||
| 0-14 years (%) | 4 (0.4) | 4 (0.8) | |
| 15-64 years (%) | 866 (76.8) | 372 (76.9) | |
| >64 years (%) | 258 (22.9) | 108 (22.3) | |
| Male gender (%) | 758 (67.2) | 344 (71.1) | 0.125 |
| Ethnicity: | 0.136 | ||
| Chinese | 679 (60.2) | 297 (61.4) | |
| Indian | 87 (7.7) | 26 (5.4) | |
| Malay | 171 (15.2) | 64 (13.2) | |
| Others | 191 (16.9) | 97 (20.0) | |
| Singapore resident (%) | 779 (69.1) | 321 (66.3) | 0.279 |
| Multidrug-resistant isolate (%) | 33 (2.9) | 58 (12.0) | <0.001 |
| Molecular profiling1 | |||
| Number of clusters | 102 | 42 | N.A.2 |
| Patients clustered (%) | 347 (30.8) | 133 (27.5) | 0.186 |
| Lineage: | 0.061 | ||
| Beijing (%) | 493 (43.7) | 246 (50.8) | |
| EAI (%) | 269 (23.8) | 98 (20.2) | |
| NEW-1 (%) | 36 (3.2) | 7 (1.4) | |
| Haarlem (%) | 30 (2.7) | 10 (2.1) | |
| CAS (%) | 17 (1.5) | 5 (1.0) |
1 Isolates were clustered based on identical spoligotyping and MIRU-VNTR profiles.
2 N.A. = not applicable.